| Category | Dissolving Microneedle · Upstream Material |
| Founded | 2000 |
| Headquarters | Jinan |
| Listing | STAR Market-listed · 688363.SH (Nov 2019) |
| Latest revenue | FY2025 revenue RMB 4.20bn, net profit RMB 291m |
| Hero SKUs | Medical-Grade Sodium Hyaluronate |
Brand History
Bloomage is one of the world's major sodium hyaluronate suppliers, spanning raw materials, medical terminals, functional skincare and food. In dissolving microneedles its role is upstream: most dissolvable matrices use sodium hyaluronate as a backbone, making Bloomage's medical and cosmetic grades a foundational input for the category.
Bloomage listed on the STAR Market in November 2019 (688363). Revenue fell from RMB 6.08bn in 2023 to RMB 5.37bn in 2024 and RMB 4.20bn in 2025 (-21.82%), dragged by functional skincare, while net profit recovered to RMB 291m, up about 67%, as marketing spend was cut. For microneedles, its significance is not consumer products but the stability of raw material and fermentation — which determines whether patches can be produced at scale and low cost.
Hero Products
Three-Year Financials
| Year | Revenue (RMB bn) | YoY | Net profit (RMB bn) |
|---|---|---|---|
| 2023 | 60.76 | -4.45% | 5.93 |
| 2024 | 53.71 | -11.6% | 1.74 |
| 2025 | 41.99 | -21.82% | 2.91 |
Brand-level：Microneedles are not a standalone Bloomage business; its role is upstream, supplying medical-grade sodium hyaluronate and matrix materials. Its 2025 skin-science conversion business fell 42.1% to RMB 1.49bn.
Source：Bloomage annual reports 2023-2025
Company Coverage
- 2026-04FY2025: RMB 4.20bn revenue, RMB 291m net profit
Revenue fell 21.82% while profit rose about 67% on lower spending.
Source：Annual report - 2025-11Upstream capacity expands
Medical-grade HA capacity and grades extended for aesthetics and microneedle customers.
Source：Company filings - 2025-07New ingredients from synthetic biology
New materials widen the actives microneedles can carry.
Source：Company filings